DHCR24 Antibody

What is DHCR24 and why is it significant in research?

DHCR24, also known as Seladin-1 or Diminuto/dwarf1, is a member of the flavin adenine dinucleotide (FAD)-dependent oxidoreductases that catalyzes the reduction of the delta-24 double bond in sterol intermediates during cholesterol biosynthesis. This enzyme is predominantly expressed in the adrenal gland and brain, where it is localized to the endoplasmic reticulum or Golgi apparatus . Its significance stems from its involvement in:

• Cholesterol metabolism maintenance

• Cellular membrane integrity

• Association with desmosterolosis when defective

• Potential role as a biomarker for hepatitis C-related liver diseases

• Implications in tumor progression and diagnosis

The enzyme's down-regulation in certain disease states makes it a valuable target for immunological studies.

What are the primary applications of DHCR24 antibodies in laboratory research?

DHCR24 antibodies have demonstrated utility across multiple experimental platforms:

Research demonstrates that DHCR24 antibodies can effectively detect the protein in various human and murine samples, including liver tissue, breast cancer tissue, and multiple cell lines such as HepG2, Jurkat, and MCF-7 .

How should researchers select the appropriate DHCR24 antibody for their experimental needs?

Selection should be guided by:

• Target species reactivity: Most commercial antibodies react with human and mouse DHCR24, with some showing rat cross-reactivity

• Application compatibility: Verify the antibody has been validated for your specific application

• Antibody format: Consider whether native or conjugated forms (HRP, FITC, PE, etc.) are needed

• Clonality considerations:

  • Monoclonal antibodies (e.g., C59D8, A-4) offer consistent reproducibility and specificity

  • Polyclonal antibodies provide broader epitope recognition, potentially enhancing sensitivity

• Immunogen design: Some antibodies target specific regions (e.g., N-terminal peptides 57-87)

For novel applications, preliminary validation experiments comparing multiple antibodies are recommended.

What are the optimal protocols for using DHCR24 antibodies in immunohistochemistry?

For successful DHCR24 IHC staining:

• Tissue preparation:

  • Formalin-fixed, paraffin-embedded (FFPE) sections (5μm thickness)

  • Heat-mediated antigen retrieval is critical using either:

    • TE buffer (pH 9.0) (preferred method)

    • Citrate buffer (pH 6.0) as an alternative

• Staining protocol:

  • Blocking: 1-2 hours with appropriate blocking solution (e.g., 1% Block Ace/PBS-0.1% Tween 20)

  • Primary antibody: Dilute to 1:50-1:500 depending on the specific antibody

  • Incubation: Overnight at 4°C or 1-2 hours at room temperature

  • Detection: Use appropriate species-specific secondary antibody systems

• Positive control tissues:

  • Human liver tissue

  • Mouse liver tissue

  • Human breast cancer tissue

How can researchers develop an effective ELISA system using DHCR24 antibodies for biomarker studies?

Based on published methodologies for DHCR24 auto-antibody detection :

• Antigen preparation:

  • Purified DHCR24 from HuH-7 cells shows superior reactivity compared to E. coli-expressed recombinant protein

  • Coat plates with 2μg/mL purified antigen in 50mM Na2CO3 buffer (pH 9.0)

  • Incubate overnight at 4°C

• ELISA protocol optimization:

  • Blocking: 1% Block Ace/PBS-0.1% Tween 20 at 37°C for 1-2 hours

  • Sample dilution: 1:100 in blocking buffer

  • Controls: Include mouse polyclonal anti-DHCR24 sera (0.5-2μg/mL) as positive controls

  • Secondary antibody: Peroxidase-conjugated anti-human IgG (1:1000) for patient samples

  • Detection limit: Approximately 0.05μg/mL

• Standard curve development:

  • Use mouse anti-DHCR24 as a standard

  • Establish a dose-response relationship between antibody concentration (0-2μg/mL) and optical density

This protocol has successfully distinguished between DHCR24 antibody levels in healthy controls versus patients with chronic hepatitis, liver cirrhosis, and HCC.

What validation steps are essential when implementing DHCR24 antibodies in new research contexts?

Comprehensive validation requires:

• Specificity confirmation:

  • Western blot should show bands at the expected molecular weight (50-60kDa)

  • Include positive control samples (e.g., HepG2 cells, liver tissue)

  • Conduct knockdown/knockout experiments as negative controls

• Cross-reactivity assessment:

  • Test across multiple species if cross-species applications are planned

  • Evaluate potential cross-reactivity with related proteins in the sterol reductase family

• Application-specific optimization:

  • Titrate antibody concentrations for each application (e.g., 1:500-1:1000 for WB, 1:50-1:500 for IHC)

  • Test multiple antigen retrieval methods for IHC applications

  • Optimize blocking conditions to minimize background

• Reproducibility verification:

  • Perform technical and biological replicates

  • Document lot-to-lot variation if using multiple antibody batches

How effective is serum DHCR24 antibody as a biomarker for HCV-related liver disease progression?

Studies evaluating DHCR24 antibody as a biomarker reveal promising diagnostic potential:

• Diagnostic performance metrics:

  • Sensitivity: 70.06% (95% CI: 62.73-76.70%)

  • Specificity: 84.21% (95% CI: 76.88-89.95%)

  • Optimal cutoff value: 11.5μg/mL

• Comparative advantage over established markers:

  Marker	Sensitivity	Specificity	Cutoff
  DHCR24 Ab	70.06%	84.21%	11.5μg/mL
  AFP	53.49%	97.66%	20ng/mL
  PIVKA-II	42.51%	100%	40mIU/mL

• Disease progression correlation:

  • Significant elevation in HCV-infected patients compared to healthy controls

  • Progressive increase from chronic hepatitis to liver cirrhosis

  • Further elevation in HCC patients

  • Particularly valuable for detecting AFP-negative and PIVKA-II-negative HCC cases

• Specificity to HCV etiology:

  • DHCR24 antibody shows higher discriminatory power in HCV-related liver disease compared to HBV-related cases

  • This specificity suggests unique pathophysiological mechanisms in HCV infection

These findings indicate DHCR24 antibody has potential as both a prognostic marker for HCV disease progression and a diagnostic marker for HCC in patients with chronic HCV infection.

What mechanisms explain the relationship between DHCR24 expression and tumor development?

Research has identified several pathways linking DHCR24 to oncogenesis:

• Cholesterol metabolism influence:

  • DHCR24 regulates cellular cholesterol synthesis

  • Altered cholesterol metabolism provides tumor cells with building blocks for membrane synthesis and proliferation

  • Inhibition of DHCR24 can decrease intracellular cholesterol levels and suppress tumor growth

• Regulatory interactions:

  • Multiple molecular pathways regulate DHCR24 expression:

    • miRNA interactions (miR-892b, miR-217-5p, miR-7, miR-124)

    • Circular RNA regulation (hsa_circ_0003221, CircEZH2)

    • Hormone responsiveness (estrogen, androgen)

• Tumor-specific regulation:

  • DHCR24 is upregulated specifically in HCV-positive tissues but not in HBV-positive tissues

  • DHCR24 protein can be internalized after surface activation, influencing cholesterol synthesis and tumor progression

• Therapeutic targeting potential:

  • Monoclonal antibody 2-152a MAb recognizes the cell surface domain of DHCR24

  • Shows unique anti-HCV activity

  • Potential for targeted therapy of HCV-related HCC

  • Other inhibitors like GD demonstrate anti-tumor activity by inhibiting DHCR24-induced cholesterol biosynthesis

How do experimental conditions affect DHCR24 antibody detection in complex tissue samples?

Several factors influence detection efficacy:

• Antigen retrieval optimization:

  • TE buffer (pH 9.0) generally yields superior results than citrate buffer (pH 6.0)

  • Heat-mediated retrieval is essential for formalin-fixed samples

• Tissue-specific considerations:

  • Liver tissue shows strongest immunoreactivity, consistent with DHCR24's metabolic role

  • Breast cancer tissue demonstrates variable staining patterns

  • Brain tissue may require modified protocols due to lipid content

• Sample preparation variables:

  • Fixation duration significantly impacts epitope accessibility

  • Fresh-frozen samples may provide higher sensitivity but reduced morphological detail

  • Paraffin embedding can mask epitopes requiring more aggressive retrieval methods

• Detection system selection:

  • Amplification systems (e.g., tyramide signal amplification) may be necessary for low-abundance detection

  • Fluorescent detection allows for multiplexing with other markers

  • Chromogenic detection provides better morphological context and stability

What strategies can address inconsistent results when using DHCR24 antibodies?

When encountering reproducibility issues:

• Antibody-related troubleshooting:

  • Verify antibody stability and storage conditions (-20°C, avoid repeated freeze-thaw cycles)

  • Use fresh aliquots for critical experiments

  • Test multiple antibody lots if available

  • Consider switching between monoclonal and polyclonal antibodies to verify findings

• Protocol optimization:

  • For Western blotting: Adjust protein loading (10-30μg), blocking conditions, and antibody incubation times

  • For IHC: Systematically test multiple antigen retrieval methods and detection systems

  • For ELISA: Optimize coating concentration, blocking solutions, and sample dilutions

• Sample preparation refinement:

  • Ensure complete protein denaturation for WB applications

  • Include protease and phosphatase inhibitors in lysis buffers

  • Consider native versus reducing conditions based on epitope characteristics

• Controls implementation:

  • Include positive controls (HepG2 cells, liver tissue)

  • Implement technical replicates to assess method variability

  • Consider DHCR24-knockdown samples as negative controls

How should researchers interpret contradictory findings when studying DHCR24 in different disease contexts?

When facing conflicting results:

• Disease etiology considerations:

  • DHCR24 shows distinct expression patterns in HCV versus HBV-related liver disease

  • Different cancer types may exhibit opposite DHCR24 regulation patterns

• Methodological reconciliation:

  • Compare antibody clones and epitopes used across studies

  • Assess differences in quantification methods (e.g., Western blot densitometry versus RT-qPCR)

  • Consider how sample processing might affect results (FFPE versus frozen tissue)

• Biological heterogeneity assessment:

  • Patient demographics and disease stage significantly impact DHCR24 expression

  • Consider the influence of concomitant metabolic conditions given DHCR24's role in cholesterol synthesis

  • Evaluate tumor heterogeneity as a source of variation

• Integrated data analysis:

  • Triangulate findings using multiple detection methods

  • Correlate protein expression with mRNA levels and functional outcomes

  • Consider meta-analysis approaches when applicable

What experimental design considerations are crucial for studies evaluating DHCR24 as a potential therapeutic target?

For therapeutic targeting studies:

• Model system selection:

  • Cell line models should reflect the disease context (e.g., HepG2 for HCC studies)

  • Patient-derived xenografts may better recapitulate tumor heterogeneity

  • Consider both in vitro and in vivo validation

• Intervention approach design:

  • Antibody-based approaches: Consider both neutralizing effects and potential for internalization

  • Small molecule inhibitors: Target DHCR24 enzymatic function

  • Genetic modulation: Use inducible systems to assess temporal effects of DHCR24 suppression

• Endpoint assessment:

  • Measure both direct (DHCR24 activity, cholesterol levels) and indirect (cell proliferation, tumor growth) outcomes

  • Assess potential compensation by other cholesterol synthesis pathway enzymes

  • Evaluate combination approaches with established therapies (e.g., doxorubicin, paclitaxel)

• Specificity validation:

  • Demonstrate on-target effects through rescue experiments

  • Assess potential off-target effects on related sterol metabolism enzymes

  • Evaluate effects in normal versus disease tissues to establish therapeutic window

What emerging applications of DHCR24 antibodies might advance personalized medicine approaches?

Several promising directions include:

• Combination biomarker panels:

  • Integration of DHCR24 antibody measurements with established markers (AFP, PIVKA-II)

  • Development of risk stratification algorithms for HCV patients

  • Correlation with imaging findings for enhanced early detection

• Therapeutic monitoring applications:

  • Tracking DHCR24 antibody levels during antiviral therapy

  • Assessing response to cholesterol-lowering interventions

  • Monitoring for disease recurrence after treatment

• Novel antibody engineering approaches:

  • Development of bispecific antibodies targeting DHCR24 and other cancer markers

  • Antibody-drug conjugates for targeted delivery to DHCR24-expressing tumors

  • Engineered antibody fragments with enhanced tissue penetration

• Theranostic applications:

  • Dual-purpose antibodies for both imaging and therapeutic intervention

  • Integration with emerging liquid biopsy approaches

  • Development of companion diagnostics for DHCR24-targeted therapies

These applications could transform DHCR24 antibodies from research tools into clinically valuable assets for precision medicine.